STING1 and STING-associated vasculopathy with onset in infancy: The SAVI syndrome is a rare autoinflammatory disorder driven by gain‐of‐function mutations in STING, such as V147L, N153S, and V155M.[6] Currently, the only promising therapeutic option in clinics is the Janus kinase (JAK) inhibitors.[63, 64] We evaluated the potential of 4‐PBA to counteract the hyperactive signaling associated with SAVI‐linked STING mutants, focusing on the V147L, N153S, and V155M variants.